Predicting and Taming Immunogenicity: Strategies for your Biologic Drug
Immunogenicity is the ability of a foreign substance, such as a drug or vaccine, to…
Certara2021 年 11 月 19 日
Dose Optimization Using Population PK for an Orphan Drug
RAPALIMUS® Tablets (sirolimus) is Nobelpharma’s orphan drug developed from an oral medication that is sold…
Certara2021 年 11 月 17 日
A day in the life of a clinical pharmacology consultant
Strategic consulting within drug discovery and development is an exciting career choice for many. Unlike…
Certara2021 年 10 月 8 日
生物制剂的临床药理计划是怎样的？
Monoclonal antibodies are now widely used in the treatment of several diseases, providing effective and…
Certara2021 年 8 月 6 日
Key considerations to ensure maximal probability of antibody drug conjugate development success
Antibody drug conjugates (ADC) are a unique way to obliterate tumor cells and represent an…
Certara2021 年 7 月 8 日
8 tips for successfully developing oligonucleotide therapies
By Eva Gil Berglund and Nathalie H Gosselin Oligonucleotide therapeutics are a validated class of…
Certara2021 年 2 月 1 日
“Where do I start?”: Strategies for selecting the first dose for human clinical trials
This guide to dose selection for first-in-human studies explains the conceptual framework, methods, and tools…
Certara2020 年 12 月 22 日
Using a pharmacology to payer framework to support product development
Modeling and simulation (M&S) of complex systems has primarily advanced vertically in differing scientific domains…
Certara2018 年 3 月 16 日
